论文部分内容阅读
【世界核新闻网站2016年2月29日报道】美国核管会(NRC)已批准为Shine医疗技术公司(Shine Medical Technologies)发放在威斯康星州简斯维尔(Janesville)建设一座医用放射性同位素生产设施的许可证。该设施将使用加速器驱动次临界装置(而不是反应堆)来辐照低浓铀靶溶液,从而生产多种重要医用同位素,包括钼-99。这将是全球首座获准使用这项技术的同位素
[World Nuclear News Web site February 29, 2016] The U.S. National Nuclear Corporation (NRC) has approved Shine Medical Technologies’ approval to build a medical radioisotope manufacturing facility in Janesville, Wis. license. The facility will use accelerator-driven subcritical units (rather than reactors) to irradiate low-enriched uranium target solutions to produce a variety of important medical isotopes, including molybdenum-99. This will be the first isotope in the world to be licensed for this technology